MapLight Therapeutics

In Vivo's editors, along with experts from the wider Citeline team, have selected our top four picks for the most significant M&A, alliance and financing deals of 2023. Vote now in the polls below. T

The slowdown in financings across the biopharmaceutical spectrum hit private and public companies alike in 2023 and the latest venture capital fundraising data from Evaluate indicate that last year di

The end of 2023 is proving no different from the end of any other year, with venture capital firms and biopharmaceutical companies closing out a flurry of new VC funds and financings before December d

October ended and November began with the announcement of three new venture capital and equity funds with more than $1.3bn for health care, life science and biopharmaceutical investments. Revelation P